Propofol

Active ingredient: Propofol

In short: Propofol injectable emulsion is an intravenous general anesthetic and sedation drug indicated for: •Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age •Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age •Initiation and Maintenanc

Forms & strengthsPropofol Injectable Emulsion, USP is available in single-dose vial as follow: 200 mg of propofol per 20 mL of an oil-in-water emulsion (10 mg per mL), 20 mL vial
LabelBaxter Healthcare Corporation
Label updatedNov 06, 2026

What is Propofol used for?

Propofol injectable emulsion is an intravenous general anesthetic and sedation drug indicated for:

•Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age

•Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age

•Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients

•Sedation for Adult Patients in Combination with Regional Anesthesia

•Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients

Limitations of Use

Propofol injectable emulsion is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations .

Safety, effectiveness and dosing guidelines for propofol injectable emulsion have not been established for MAC sedation in the pediatric population; therefore, it is not recommended for this use .

Propofol injectable emulsion is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established .

Propofol dosage

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Shake well before use. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing. Do not use if there is evidence of separation of the phases of the emulsion.

Propofol injectable emulsion with butylated hydroxyanisole and butylated hydroxytoluene inhibits microbial growth for up to 12 hours, as demonstrated by test data for representative USP microorganisms. Product is packaged under nitrogen.

For general anesthesia or monitored anesthesia care (MAC) sedation, propofol injectable emulsion should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Sedated patients should be continuously monitored, and equipment for maintaining a patent airway, providing artificial ventilation, administering supplemental oxygen, and instituting cardiovascular resuscitation must be immediately available. Patients should be continuously monitored for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. These cardiorespiratory effects are more likely to occur following rapid bolus administration, especially in the elderly, debilitated, or ASA-PS III or IV patients.

For sedation of intubated, mechanically ventilated adult patients in the Intensive Care Unit, propofol injectable emulsion should be administered only by persons skilled in the management of critically ill patients and trained in cardiovascular resuscitation and airway management.

Guidelines for Aseptic Technique for General Anesthesia/MAC Sedation

Propofol injectable emulsion must be prepared for use just prior to initiation of each individual anesthetic/sedative procedure. The vial rubber stopper should be disinfected using 70% isopropyl alcohol. Propofol injectable emulsion should be drawn into a sterile syringe immediately after a vial is opened. When withdrawing propofol injectable emulsion from vials, a sterile vent spike should be used. The syringe should be labelled with appropriate information including the date and time the vial was opened. Administration should commence promptly and be completed within 12 hours after the vial has been opened.

Propofol injectable emulsion must be prepared for single-dose only. …

How to take Propofol — instructions & advice from the label

Advise patients that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery or signing legal documents may be impaired for some time after general anesthesia or sedation.

Studies conducted in young animals and children suggest repeated or prolonged use of general anesthetic or sedation drugs in children younger than 3 years may have negative effects on their developing brains. Discuss with parents and caregivers the benefits, risks, and timing and duration of surgery or procedures requiring anesthetic and sedation drugs.

Manufactured by:

Baxter Pharmaceuticals India Private Ltd

Ahmedabad 382213, India

Manufactured for:

Baxter Healthcare Corporation

Deerfield, IL 60015 USA

Baxter is a registered trademark of Baxter International Inc.

Warnings & precautions

Do not take this medicine if: Propofol injectable emulsion is contraindicated in patients with a known hypersensitivity to propofol or any of propofol injectable emulsion components.

Propofol injectable emulsion is contraindicated in patients with a history of anaphylaxis to eggs, egg products, soybeans or soy products.

Use of propofol injectable emulsion has been associated with both fatal and life threatening anaphylactic and anaphylactoid reactions.

Clinical features of anaphylaxis, including angioedema, bronchospasm, erythema, and hypotension, occur rarely following propofol injectable emulsion administration.

Strict aseptic technique must always be maintained during handling. Propofol injectable emulsion is a single-dose parenteral product (single patient infusion vial) which contains 0.0000024% of butylated hydroxyanisole and 0.00001% butylated hydroxytoluene to inhibit the rate of growth of microorganisms, for up to 12 hours, in the event of accidental extrinsic contamination. However, propofol injectable emulsion can still support the growth of microorganisms, as it is not an antimicrobially preserved product under USP standards. Do not use if contamination is suspected. Discard unused drug product as directed within the required time limits. There have been reports in which failure to use aseptic technique when handling propofol injectable emulsion was associated with microbial contamination of the product and with fever, infection/sepsis, other life-threatening illness, and/or death.

Propofol injectable emulsion vials are never to be accessed more than once or used on more than one person.

There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and of the use of propofol vials intended for single use on multiple persons. …

Propofol side effects

The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling:

•Hypersensitivity reaction

•Hypotension and/or bradycardia

•Propofol Infusion Syndrome

In the description below, rates of the more common events represent US/Canadian clinical study results. Less frequent events are also derived from publications and marketing experience in over 8 million patients; there are insufficient data to support an accurate estimate of their incidence rates. These studies were conducted using a variety of premedicants, varying lengths of surgical/diagnostic procedures, and various other anesthetic/sedative agents. Most adverse events were mild and transient.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Anesthesia and MAC Sedation in Adults

The following estimates of adverse events for propofol injectable emulsion include data from clinical trials in general anesthesia/MAC sedation (N=2,889 adult patients). The adverse events listed below as probably causally related are those events in which the actual incidence rate in patients treated with propofol injectable emulsion was greater than the comparator incidence rate in these trials. …

Drug interactions

Opioids and Sedatives

The induction dose requirements of propofol injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol injectable emulsion and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output.

In pediatric patients, administration of fentanyl concomitantly with propofol injectable emulsion may result in serious bradycardia.

Analgesic Agents

During maintenance of anesthesia or sedation, the rate of propofol injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (e.g., nitrous oxide or opioids).

The concurrent administration of potent inhalational agents (e.g., isoflurane, sevoflurane, desflurane, enflurane, and halothane) during maintenance with propofol injectable emulsion are routinely used. …

About this medicine

Propofol Injectable Emulsion, USP is a sterile, nonpyrogenic white milky emulsion free from extraneous particulate contamination and large oil droplets for intravenous administration. The structural formula is:

Chemical name: 2,6 Diisopropylphenol

Molecular formula: C12H18O

Molecular weight: 178.27 g/mol

Propofol, USP is clear, colorless to slightly yellowish liquid. It is Very soluble in methanol and in ethanol; slightly soluble in cyclohexane and in isopropyl alcohol; very slightly soluble in water. Miscible with hexane. The pKa is 11. The octanol/water partition coefficient for propofol is 6761:1 at a pH of 6 to 8.5.

Each mL of Propofol injectable emulsion, USP contains 10 mg of propofol, USP; 100 mg of soybean oil, USP (100 mg/mL); 22.5 mg of glycerol, USP (22.5 mg/mL); 12 mg of egg lecithin, NF (12 mg/mL); 0.000024 mg of butylated hydroxyanisole, NF (0.000024 mg/mL) and 0.0001 mg butylated hydroxytoluene, NF (0.0001 mg/mL) as microbial inhibitor, and sodium hydroxide to adjust pH, in water for injection. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 76ae0147-53ad-4192-a400-c5d1760123d0. Read the full official label on DailyMed.